Perception of quality of life by patients, partners and treating physicians

被引:191
作者
Wilson, KA
Dowling, AJ
Abdolell, M
Tannock, IF
机构
[1] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[2] Princess Margaret Hosp, Dept Biostat, Toronto, ON M5G 2M9, Canada
[3] Univ Toronto, Toronto, ON, Canada
关键词
cancer; proxy; quality of life;
D O I
10.1023/A:1016647407161
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The objective of the study was to determine possible differences in perception of quality of life (QoL) between patients with metastatic breast or prostate cancer, their partners, and the treating physician. Patients with metastatic breast cancer (n = 71), and metastatic prostate cancer (n = 29), a partner, and the physician each completed the same QoL questionnaire indicating how they perceived the patient's QoL. The European organization for research and treatment of cancer (EORTC) QLQ-C30 questionnaire was used to assess patients with breast cancer and the modified prostate cancer specific quality of life instrument (PROSQOLI) for patients with prostate cancer. There was reasonable agreement in mean scores between patients, and physicians or partners, for many domains of QoL; however, there was substantial discordance between scores when considering individual patients. For patients with metastatic breast cancer, physicians systematically underestimated overall QoL (p = 0.0002). social functioning (p = 0.001). and role functioning (p = 0.008), while partners showed better agreement. With prostate cancer physicians tended to underestimate pain, while mean scores for spouses were more concordant. There is substantial variability between ratings of QoL by physicians or partners, as compared to patient ratings. Medical decisions should be based on information about QoL provided by patients using validated methods.
引用
收藏
页码:1041 / 1052
页数:12
相关论文
共 35 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
[Anonymous], J CLIN ONCOL
[3]  
Bartko JJ, 1996, PSYCHOL REP, V19, P3
[4]  
Bishop J F, 1997, Oncology (Williston Park), V11, P19
[5]   OBSERVER VARIATION IN ASSESSMENT OF QUALITY-OF-LIFE IN PATIENTS WITH ESOPHAGEAL CANCER [J].
BLAZEBY, JM ;
WILLIAMS, MH ;
ALDERSON, D ;
FARNDON, JR .
BRITISH JOURNAL OF SURGERY, 1995, 82 (09) :1200-1203
[6]   A DECADE OF BREAST-CANCER CLINICAL INVESTIGATION - RESULTS AS REPORTED IN THE PROGRAM/PROCEEDINGS OF THE AMERICAN-SOCIETY-OF-CLINICAL-ONCOLOGY [J].
CHLEBOWSKI, RT ;
LILLINGTON, LM .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1789-1795
[7]   IMPROVING THE QUALITY-OF-LIFE DURING CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A COMPARISON OF INTERMITTENT AND CONTINUOUS TREATMENT STRATEGIES [J].
COATES, A ;
GEBSKI, V ;
BISHOP, JF ;
JEAL, PN ;
WOODS, RL ;
SNYDER, R ;
TATTERSALL, MHN ;
BYRNE, M ;
HARVEY, V ;
GILL, G ;
SIMPSON, J ;
DRUMMOND, R ;
BROWNE, J ;
VANCOOTEN, R ;
FORBES, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (24) :1490-1495
[8]  
DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO
[9]  
2-7
[10]   REPRODUCIBILITY ALONG A 10-CM VERTICAL VISUAL ANALOG SCALE [J].
DIXON, JS ;
BIRD, HA .
ANNALS OF THE RHEUMATIC DISEASES, 1981, 40 (01) :87-89